Table 2 Adverse events reported by ≥5.0% of subjects in any treatment arm in the STAR study [27]
From: Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for Pseudobulbar Affect
| Adverse event | Incidence, N (% of group) | ||
|---|---|---|---|
| DM/Q 30/10 mg (N = 110) | DM/Q 20/10 mg (N = 107) | Placebo (N = 109) | |
| Fall | 22 (20.0) | 14 (13.1) | 22 (20.2) |
| Dizziness | 20 (18.2) | 11 (10.3) | 6 (5.5) |
| Headache | 15 (13.6) | 15 (14.0) | 17 (15.6) |
| Nausea | 14 (12.7) | 8 (7.5) | 10 (9.2) |
| Diarrhea | 11 (10.0) | 14 (13.1) | 7 (6.4) |
| Somnolence | 11 (10.0) | 9 (8.4) | 10 (9.2) |
| Fatigue | 9 (8.2) | 11 (10.3) | 10 (9.2) |
| Nasopharyngitis | 9 (8.2) | 6 (5.6) | 8 (7.3) |
| Urinary tract infection | 8 (7.3) | 4 (3.7) | 3 (2.8) |
| Constipation | 7 (6.4) | 7 (6.5) | 9 (8.3) |
| Muscle spasms | 7 (6.4) | 4 (3.7) | 10 (9.2) |
| Muscle weakness | 6 (5.5) | 5 (4.7) | 4 (3.7) |
| Dysphagia | 5 (4.5) | 6 (5.6) | 4 (3.7) |
| Pain in extremity | 5 (4.5) | 2 (1.9) | 8 (7.3) |
| Depression | 0 (0.0) | 1 (0.9) | 6 (5.5) |